James W Mier

US Patent:

20130202594, Aug 8, 2013

Filed:

Feb 1, 2013

Appl. No.:

13/757672

Inventors:

Rupal S. BHATT - Roslindale MA, US
Ravindra Kumar - Acton MA, US
James W. Mier - Brookline MA, US
Robert Pearsall - Woburn MA, US
Matthew Sherman - Newton MA, US
Nicolas Solban - Brighton MA, US

International Classification:

A61K 38/45
A61K 31/404
A61K 31/44
A61K 31/436
A61K 31/4439
A61K 31/4709
A61K 31/517
A61K 39/395
A61K 31/506

US Classification:

4241341, 424 945, 4241391

Abstract:

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.

US Patent:

20180369167, Dec 27, 2018

Filed:

Dec 14, 2016

Appl. No.:

16/062004

Inventors:

- Cambridge MA, US
- Washington DC, US
- Boston MA, US
James W. Mier - Brookline MA, US
David McDermott - Milton MA, US

International Classification:

A61K 31/122
A61K 31/404
A61K 31/506
A61K 31/4184
A61P 35/00
A61K 31/4439

Abstract:

The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.